## Background: Topotecan is a new antineoplastic agent with a broad spectrum of activity. the purpose of this phase i trial was to define the maximum tolerated dose of topotecan when added to the widely used combination of paclitaxel and carboplatin. ## Methods: Patients with advanced cancer that
β¦ LIBER β¦
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors
β Scribed by Robert J. Morgan; Timothy Synold; Adam Mamelak; Dean Lim; Zaid Al-Kadhimi; Przemyslaw Twardowski; Lucille Leong; Warren Chow; Kim Margolin; Stephen Shibata; George Somlo; Yun Yen; Paul Frankel; James H. Doroshow
- Publisher
- Springer
- Year
- 2010
- Tongue
- English
- Weight
- 258 KB
- Volume
- 66
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Phase I trial of paclitaxel, carboplatin
β
John D. Hainsworth; Howard A. Burris III; Lisa H. Morrissey; F. Anthony Greco
π
Article
π
1999
π
John Wiley and Sons
π
English
β 72 KB
π 3 views
Hyperthermia for the treatment of patien
β
RΓΌdiger Wessalowski; Heidi Kruck; Hildegard Pape; Thomas Kahn; Reinhart Willers;
π
Article
π
1998
π
John Wiley and Sons
π
English
β 151 KB
π 3 views
waves in combination with platinum-based chemotherapy in ten children and 4 Institute of Statistics, Heinrich-Heine Univeradolescents with recurrent or refractory GCTs. sity, Du Β¨sseldorf, Germany. ## RESULTS. Seven of ten patients with recurrent or refractory GCTs had objective responses. Of the